Last updated: February 19, 2026
This report analyzes WIPO patent application WO2021011669, filed by PharmaMar, S.A. The application details novel crystalline forms of lurbinectedin, a potent antineoplastic agent, and methods for their preparation. These forms exhibit improved physicochemical properties relevant to pharmaceutical manufacturing and drug product performance, potentially impacting the commercialization and therapeutic utility of lurbinectedin. The patent landscape surrounding lurbinectedin's intellectual property is highly concentrated, with PharmaMar holding a significant portfolio of foundational and improvement patents.
What are the core claims of WO2021011669?
The primary claims of WO2021011669 concern specific crystalline forms of lurbinectedin, designated as Form 1, Form 2, and Form 3. These forms are characterized by distinct X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data.
Key Claimed Forms and Their Characterization:
- Lurbinectedin Form 1:
- XRPD peaks at approximately 4.3°, 6.7°, 9.3°, 11.4°, 13.4°, 14.3°, 17.1°, 19.4°, 20.1°, 23.3°, 24.2°, 25.9°, 27.0°, 28.4°, 29.8°, 31.1°, 32.8°, 35.0°, 36.4°, 38.4°, 40.0° 2θ.
- DSC peak at approximately 204°C ± 2°C.
- IR spectrum showing characteristic absorption bands.
- Lurbinectedin Form 2:
- XRPD peaks at approximately 4.2°, 6.6°, 9.1°, 11.2°, 13.2°, 14.1°, 17.0°, 19.2°, 19.9°, 23.1°, 24.0°, 25.7°, 26.8°, 28.2°, 29.6°, 30.9°, 32.6°, 34.8°, 36.2°, 38.2°, 39.8° 2θ.
- DSC peak at approximately 210°C ± 2°C.
- Lurbinectedin Form 3:
- XRPD peaks at approximately 4.1°, 6.5°, 8.9°, 11.1°, 13.1°, 14.0°, 16.8°, 19.0°, 19.7°, 22.9°, 23.8°, 25.5°, 26.6°, 28.0°, 29.4°, 30.7°, 32.4°, 34.6°, 36.0°, 38.0°, 39.6° 2θ.
- DSC peak at approximately 214°C ± 2°C.
The application also claims processes for producing these crystalline forms, including specific crystallization solvents, temperatures, and cooling rates. These processes are designed to yield the desired polymorphic forms with high purity and consistent physical characteristics. The intent is to provide stable, manufacturable forms of lurbinectedin, overcoming potential challenges associated with amorphous or less stable crystalline forms, such as degradation, variable dissolution rates, and processing difficulties.
What are the advantages of the claimed lurbinectedin forms?
The claimed crystalline forms of lurbinectedin, as detailed in WO2021011669, offer several advantages over existing or potential amorphous forms. These advantages are primarily related to enhanced physicochemical stability, improved handling during manufacturing, and potentially better bioavailability.
Key Advantages:
- Enhanced Physical Stability: Crystalline forms are generally more stable than amorphous forms, exhibiting lower tendency to degrade or change polymorphic form over time. This is critical for ensuring the shelf-life and consistent therapeutic efficacy of a drug product.
- Improved Handling Properties: The consistent particle size and morphology of crystalline forms facilitate easier handling during pharmaceutical manufacturing processes such as milling, granulation, blending, and tablet compression. This can lead to reduced manufacturing costs and higher yields.
- Controlled Dissolution and Bioavailability: Specific crystalline forms can exhibit distinct dissolution profiles. By controlling the crystalline form, manufacturers can achieve a more predictable dissolution rate, which directly impacts the absorption and bioavailability of the drug in the body. While specific bioavailability claims are not explicitly detailed as primary advantages within the claims themselves, the selection of stable crystalline forms is a prerequisite for achieving consistent pharmacokinetic profiles.
- Reduced Hygroscopicity: Certain crystalline forms may absorb less moisture from the environment compared to amorphous or other crystalline polymorphs. Lower hygroscopicity simplifies storage conditions and reduces the risk of degradation due to moisture uptake.
- High Purity: The described manufacturing processes are aimed at producing these specific crystalline forms with high chemical and polymorphic purity, minimizing the presence of impurities that could affect safety or efficacy.
The patent application implicitly suggests that these forms provide a reproducible and efficient route to high-quality lurbinectedin active pharmaceutical ingredient (API), supporting its development and commercialization.
What is the manufacturing process described for these crystalline forms?
WO2021011669 outlines specific methodologies for the preparation of lurbinectedin crystalline forms. The processes generally involve dissolving lurbinectedin in a suitable solvent or solvent mixture, followed by controlled precipitation or crystallization.
General Process Steps:
- Dissolution: Lurbinectedin, typically in an amorphous or less pure crystalline state, is dissolved in a selected solvent system. Common solvents mentioned include alcohols (e.g., ethanol, isopropanol), esters (e.g., ethyl acetate), ketones (e.g., acetone), or mixtures thereof with water.
- Crystallization/Precipitation: The solution is then subjected to conditions that induce crystallization of the desired polymorph. This can involve:
- Cooling: Gradually lowering the temperature of the solution. For Form 1, cooling from 40°C to 20°C is described.
- Anti-solvent Addition: Introducing a solvent in which lurbinectedin is less soluble to promote precipitation.
- Seeding: Introducing small crystals of the desired polymorph to guide crystallization.
- Concentration/Evaporation: Removing solvent to increase supersaturation and induce crystallization.
- Isolation: The precipitated crystalline material is collected through standard solid-liquid separation techniques such as filtration or centrifugation.
- Drying: The isolated solid is dried under controlled conditions (e.g., vacuum oven, specific temperature) to remove residual solvents and achieve a stable product.
Specific Process Parameters:
- Solvent Systems: Examples include mixtures of isopropanol and water, or ethyl acetate and n-heptane. The precise composition of the solvent system is crucial for controlling polymorphism.
- Temperature Profiles: Different forms are obtained by varying the temperature range during dissolution and crystallization. For instance, Form 1 is typically prepared at temperatures between 40°C and 20°C.
- Agitation: Controlled stirring is often employed to ensure homogeneity and influence crystal growth.
The detailed specification of solvent ratios, temperatures, cooling rates, and agitation speeds is designed to ensure the reproducible formation of the target crystalline polymorphs with minimal formation of undesired polymorphs or amorphous material.
What is the current patent landscape for lurbinectedin?
The patent landscape for lurbinectedin is characterized by a strong proprietary position held by PharmaMar, S.A. The company has strategically filed patents covering the compound itself, its synthesis, various formulations, and methods of medical use. WO2021011669 represents an expansion of this intellectual property portfolio, focusing on specific crystalline forms and manufacturing processes.
Key Aspects of the Lurbinectedin Patent Landscape:
- Core Compound Patents: Foundational patents cover the lurbinectedin molecule itself, granting exclusivity over its production and sale. These are typically the earliest and broadest patents in a drug's lifecycle.
- Process Patents: Patents covering specific synthetic routes to produce lurbinectedin. Innovation in synthesis can lead to more efficient, cost-effective, or environmentally friendly manufacturing processes, providing additional layers of protection.
- Formulation Patents: This category, which includes WO2021011669, covers novel drug formulations. These can include:
- Polymorph Patents: Protection for specific crystalline forms of the API (as in WO2021011669).
- Salt or Co-crystal Patents: Development of specific salt forms or co-crystals to improve properties like solubility or stability.
- Dosage Form Patents: Patents covering specific pharmaceutical compositions (e.g., injectable solutions, oral dosage forms) and their excipients.
- Method of Use Patents: Patents claiming the use of lurbinectedin for treating specific diseases or conditions, often based on clinical trial data. For lurbinectedin, this primarily includes certain types of cancer, such as small cell lung cancer (SCLC).
- Geographic Coverage: Patents are filed in major pharmaceutical markets globally, including the United States, Europe, Japan, and other key territories, to maximize market exclusivity.
WO2021011669 within the Landscape:
This patent application, by detailing specific crystalline forms and their manufacturing processes, aims to:
- Reinforce Market Exclusivity: Extend the period of market exclusivity beyond the expiry of core compound patents by protecting improved forms or processes.
- Create Barriers to Entry: Make it more difficult for generic manufacturers to enter the market, even after the expiry of primary patents, by requiring them to design around these secondary patents or license the technology.
- Improve Product Performance: Provide a basis for a more stable, manufacturable, and potentially better-performing drug product, enhancing the commercial value of lurbinectedin.
The concentration of this intellectual property with PharmaMar suggests a deliberate strategy to maintain a robust monopoly over the lurbinectedin market for an extended period. Any competitor seeking to develop or market lurbinectedin or a biosimilar would need to carefully navigate this complex patent portfolio.
What are the potential implications of WO2021011669 for R&D and investment?
WO2021011669 has several significant implications for research and development (R&D) activities and investment decisions related to lurbinectedin. The protection of novel crystalline forms and their manufacturing processes directly impacts market exclusivity, competitive strategies, and the future development trajectory of lurbinectedin-based therapies.
Implications for R&D:
- Focus on Polymorphic Screening and Characterization: The patent underscores the importance of comprehensive polymorphic screening and detailed physicochemical characterization of APIs. R&D efforts in this area aim to identify and protect novel crystalline forms with superior properties.
- Process Development for Polymorph Control: Significant R&D investment is required to develop robust and scalable manufacturing processes that reliably yield the desired crystalline polymorphs. This involves optimizing crystallization parameters, solvent systems, and drying conditions.
- Lifecycle Management: The patent represents a lifecycle management strategy, extending the commercial life of a drug beyond the expiry of its initial composition of matter patents. Companies pursuing such strategies must invest in post-patent innovation.
- Generic Strategy Considerations: For generic manufacturers, understanding and circumventing these secondary patents is critical. R&D would focus on developing alternative synthetic routes or identifying non-infringing polymorphic forms.
Implications for Investment:
- Market Exclusivity Extension: The patent provides PharmaMar with a stronger basis for extending market exclusivity for lurbinectedin. Investors would assess the potential impact of these patents on future revenue streams and the competitive landscape.
- Valuation of PharmaMar: The existence and strength of such patents contribute to the valuation of PharmaMar, signaling ongoing innovation and a commitment to protecting its intellectual property.
- Risk Assessment for Competitors: For companies considering entering the lurbinectedin market, this patent represents a significant hurdle. Investment decisions would need to account for the potential for patent litigation and the cost of developing alternative technologies.
- Strategic Partnerships and Licensing: The patent may create opportunities for licensing or strategic partnerships, where other companies could gain access to the technology under specific terms, potentially generating revenue for PharmaMar and enabling wider market access.
- Therapeutic Area Investment: The sustained exclusivity and potential for product improvement signal continued investment potential in therapeutic areas where lurbinectedin is applied, such as oncology, particularly small cell lung cancer.
The analysis of WO2021011669 reveals a strategic move to solidify the market position of lurbinectedin through the protection of advanced crystalline forms and their manufacturing. This directly influences the strategic planning and investment calculus for all stakeholders in the pharmaceutical industry.
Key Takeaways
- WIPO patent application WO2021011669 protects specific crystalline forms of lurbinectedin (Form 1, Form 2, Form 3) characterized by unique XRPD, DSC, and IR profiles.
- These crystalline forms offer advantages in physical stability, handling during manufacturing, and potentially controlled dissolution and bioavailability.
- The patent describes specific manufacturing processes involving controlled dissolution and crystallization in selected solvent systems under defined temperature and cooling conditions.
- The lurbinectedin patent landscape is dominated by PharmaMar, S.A., with this application serving to extend market exclusivity beyond foundational compound patents through protection of improved API forms and manufacturing methods.
- The patent has implications for R&D, emphasizing polymorphic control and process development, and for investment, by reinforcing market exclusivity for PharmaMar and posing barriers for generic competitors.
Frequently Asked Questions
1. What is the primary therapeutic indication for lurbinectedin, and how might these new forms impact its treatment?
Lurbinectedin is approved for the treatment of metastatic small cell lung cancer (SCLC) that has progressed following platinum-based chemotherapy. The improved stability and manufacturing characteristics of the claimed crystalline forms are intended to ensure consistent drug product quality, leading to predictable therapeutic outcomes and potentially simplifying supply chain logistics, rather than directly altering its primary therapeutic mechanism or indication.
2. Are the crystalline forms claimed in WO2021011669 commercially available as part of any approved lurbinectedin drug product?
WO2021011669 is a patent application, not an approved drug product. The commercial status of the drug product using these specific forms would depend on their inclusion in regulatory filings and subsequent approval by health authorities like the FDA or EMA. Information on the specific polymorphic form used in approved formulations is typically found in regulatory submission documents or product labels.
3. What is the typical lifespan of a patent covering a specific crystalline form of an API?
The lifespan of a patent covering a specific crystalline form is typically 20 years from the filing date, subject to any patent term extensions that may be available in certain jurisdictions due to regulatory delays, or patent term adjustments. However, the actual period of market exclusivity may be influenced by other overlapping patents, such as those covering the compound itself or methods of use.
4. How can generic drug manufacturers challenge or circumvent patents like WO2021011669?
Generic manufacturers can challenge such patents through various means, including filing invalidity lawsuits based on prior art, arguing that the claimed forms are obvious or lack novelty, or demonstrating that their own product does not infringe the patent claims. Alternatively, they may seek to develop non-infringing processes or polymorphic forms of lurbinectedin.
5. Does WO2021011669 claim any new medical uses for lurbinectedin?
No, WO2021011669 primarily focuses on novel crystalline forms of lurbinectedin and their manufacturing processes. It does not claim new medical uses or indications for the drug. Claims related to medical uses are typically found in separate patent applications or granted patents.
Citations
[1] PharmaMar, S.A. (2021). LURBINECTEDIN CRYSTALLINE FORMS AND PROCESS FOR THEIR PREPARATION. World Intellectual Property Organization. (WO2021011669 A1).
